MedTrace Logo

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

NCT06066333 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.

Conditions

  • Adrenocortical Carcinoma
  • ACC
  • Metastatic Adrenocortical Carcinoma

Interventions

RADIATION

Ablative Radiotherapy

All participants will first undergo ablative RT

DRUG

Pembrolizumab

After completion of ablative RT, all subjects may begin pembrolizumab treatment

Sponsors & Collaborators

Principal Investigators

  • Nitya Raj, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2026-09-27
Completion
2026-09-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06066333 on ClinicalTrials.gov